Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation

por Nash AI, Turkoz I, Savitz AJ, Mathews M, Kim E
Publicado 2019

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study

por Gopal S, Gogate J, Pungor K, Kim E, Singh A, Mathews M
Publicado 2020

Exploring the long-term safety of asenapine in adults with schizophrenia in a double-blind, fixed-dose, extension study

por Durgam S, Landbloom RP, Mackle M, Wu X, Mathews M, Nasrallah HA
Publicado 2017

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia

por Lambert M, Sanchez P, Bergmans P, Gopal S, Mathews M, Wooller A, Pungor K
Publicado 2020

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate

por Mathews M, Nuamah I, Savitz AJ, Hough DW, Najarian D, Kim E, Gopal S
Publicado 2018

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials

por Borentain S, Williamson D, Turkoz I, Popova V, McCall WV, Mathews M, Wiegand F
Publicado 2021

Impact of time of initiation of once-monthly paliperidone palmitate in hospitalized Asian patients with acute exacerbation of schizophrenia: a post hoc analysis from the PREVAIL st...

por Li H, Li Y, Feng Y, Zhuo J, Turkoz I, Mathews M, Tan W
Publicado 2018

Effect of Concomitant Benzodiazepine Use on Efficacy and Safety of Esketamine Nasal Spray in Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior: Pooled...

por Diekamp B, Borentain S, Fu DJ, Murray R, Heerlein K, Zhang Q, Schüle C, Mathews M
Publicado 2021

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Ho...

por Mathews M, Gopal S, Singh A, Nuamah I, Pungor K, Tan W, Soares B, Kim E, Savitz AJ
Publicado 2020

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia

por Mathews M, Gopal S, Nuamah I, Hargarter L, Savitz AJ, Kim E, Tan W, Soares B, Correll CU
Publicado 2019

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase II...

por Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Hough D, Mathews M, Feng Y, Yu L, Takahashi M, Liu D, Wang G, Yoon J, Chen JJ
Publicado 2017